Interstitial lung disease
- PMID: 24591661
- PMCID: PMC9487254
- DOI: 10.1183/09059180.00009113
Interstitial lung disease
Abstract
Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial pneumonias, according to which there are three groups: major, rare and unclassified. The novelty of the new classification comes from the fact that difficult to classify entities can be treated according to the disease behaviour classification. Idiopathic pulmonary fibrosis is the most lethal amongst the interstitial lung diseases and presents high heterogeneity in clinical behaviour. A number of biomarkers have been proposed in order to predict the course of the disease and group patients with the same characteristics in clinical trials. Early diagnosis and disease stratification is also important in the field of other interstitial lung diseases.
Conflict of interest statement
Statement of Interest: None declared.
Similar articles
-
Classification and natural history of the idiopathic interstitial pneumonias.Proc Am Thorac Soc. 2006 Jun;3(4):285-92. doi: 10.1513/pats.200601-005TK. Proc Am Thorac Soc. 2006. PMID: 16738191 Free PMC article. Review.
-
Spectrum of fibrosing diffuse parenchymal lung disease.Mt Sinai J Med. 2009 Feb;76(1):2-23. doi: 10.1002/msj.20087. Mt Sinai J Med. 2009. PMID: 19170214 Review.
-
[Diffuse idiopathic interstitial pneumonias. International multidisciplinary consensus classification by the American Thoracic Society and the European Respiratory Society, principal clinico-pathological entities, and diagnosis].Rev Mal Respir. 2004 Apr;21(2 Pt 1):299-318. doi: 10.1016/s0761-8425(04)71288-7. Rev Mal Respir. 2004. PMID: 15211238 Review. French.
-
Unclassifiable interstitial lung disease: A review.Respirology. 2016 Jan;21(1):51-6. doi: 10.1111/resp.12568. Epub 2015 Jun 9. Respirology. 2016. PMID: 26059704 Review.
-
[Idiopathic diffuse interstitial lung disease].Rev Prat. 2000 Nov 1;50(17):1901-5. Rev Prat. 2000. PMID: 11151331 Review. French.
Cited by
-
Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).Exp Ther Med. 2024 Jul 30;28(4):381. doi: 10.3892/etm.2024.12670. eCollection 2024 Oct. Exp Ther Med. 2024. PMID: 39113908 Free PMC article. Review.
-
Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production.J Cell Physiol. 2021 Oct;236(10):6836-6851. doi: 10.1002/jcp.30380. Epub 2021 Apr 14. J Cell Physiol. 2021. PMID: 33855709 Free PMC article.
-
Can FDG-PET/CT imaging be used to predict decline in quality of life in interstitial lung disease? A prospective study of the relationship between FDG uptake and quality of life in a UK outpatient setting.BMJ Open. 2024 May 30;14(5):e081103. doi: 10.1136/bmjopen-2023-081103. BMJ Open. 2024. PMID: 38816048 Free PMC article.
-
Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases.PLoS One. 2022 Nov 3;17(11):e0277007. doi: 10.1371/journal.pone.0277007. eCollection 2022. PLoS One. 2022. PMID: 36327336 Free PMC article.
-
Application of Innovative 3D Pathological Tactic for Diagnosis of Organizing Pneumonia.In Vivo. 2024 Jul-Aug;38(4):1993-2000. doi: 10.21873/invivo.13656. In Vivo. 2024. PMID: 38936886 Free PMC article.
References
-
- American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304. - PubMed
-
- Thomeer M, Demedts M, Behr J, et al. . Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008; 31: 585–591. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical